1. Home
  2. JOUT vs CBIO Comparison

JOUT vs CBIO Comparison

Compare JOUT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JOUT

Johnson Outdoors Inc.

HOLD

Current Price

$44.77

Market Cap

456.3M

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$14.23

Market Cap

537.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JOUT
CBIO
Founded
1970
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
456.3M
537.5M
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
JOUT
CBIO
Price
$44.77
$14.23
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
30.4K
363.2K
Earning Date
05-08-2026
04-29-2026
Dividend Yield
2.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$592,415,000.00
$18,500.00
Revenue This Year
$11.67
N/A
Revenue Next Year
$3.70
$279.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.65
$8.72
52 Week High
$53.54
$27.41

Technical Indicators

Market Signals
Indicator
JOUT
CBIO
Relative Strength Index (RSI) 41.16 32.69
Support Level $43.02 $9.95
Resistance Level $48.01 $18.53
Average True Range (ATR) 1.32 1.40
MACD -0.01 -0.62
Stochastic Oscillator 11.48 7.09

Price Performance

Historical Comparison
JOUT
CBIO

About JOUT Johnson Outdoors Inc.

Johnson Outdoors Inc is a manufacturer and marketer of branded seasonal, outdoor recreation products used for fishing from a boat, diving, paddling, hiking and camping. The company has four operating segment: Fishing, Camping, Watercraft Recreation, and Diving. It generates maximum revenue from the Fishing segment which produces and markets products under different brands such as Minn Kota electric motors for quiet trolling or primary propulsion, marine battery chargers and shallow water anchors; Humminbird sonar and GPS equipment for fish finding, navigation and marine cartography; and Cannon downriggers for controlled-depth fishing. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe, Canada, and other regions.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: